Forty Seven (FTSV) Stock Price, News & Analysis

Company Overview

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Key Stats

• Today's Range: $95.51 to $95.51
• 50-Day Range: $95.51 to $95.51
• 52-Week Range: $5.53 to $95.51
• Volume: N/A
• Average Volume: 1.61 million shs
• Market Capitalization: $4.60 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FTSV Stock Analysis - Frequently Asked Questions

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.38) EPS for the quarter, hitting analysts' consensus estimates of ($0.38). The firm had revenue of $15.68 million for the quarter, compared to analysts' expectations of $15.80 million.

When did Forty Seven IPO?

Forty Seven (FTSV) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

What other stocks do shareholders of Forty Seven own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Forty Seven investors own include Gilead Sciences (GILD), TG Therapeutics (TGTX), Clovis Oncology (CLVS), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Abbott Laboratories (ABT) and ACADIA Pharmaceuticals (ACAD).

Company Calendar

• Last Earnings: 11/12/2019
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FTSV
• CUSIP: N/A
• CIK: N/A
• Web: www.fortyseveninc.com
• Phone: 650-352-4150
• Fax: N/A
• Employees: 57
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-87,620,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -50.38%
• Return on Assets: -44.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.81
• Quick Ratio: 14.81

Sales & Book Value

• Annual Sales: $15.68 million
• Price / Sales: 293.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.52 per share
• Price / Book: 12.70

Miscellaneous

• Outstanding Shares: 48,156,000
• Free Float: N/A
• Market Cap: $4.60 billion
• Optionable: Not Optionable
• Beta: 0.40